Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014

Date: December 10, 2014
Pages: 57
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: TA40A98A67EEN
Leaflet:

Download PDF Leaflet

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview
Therapeutics Development
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development
Altor BioScience Corporation
AstraZeneca PLC
Boston Biomedical, Inc.
Daiichi Sankyo Company, Limited
Dendreon Corporation
Mirati Therapeutics Inc.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Limited
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALT-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBI-503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dovitinib lactate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lapuleucel-t - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tigatuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2014
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca PLC, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Dendreon Corporation, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2014
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
Skip to top


Squamous Cell Carcinoma - Pipeline Review, H2 2014 US$ 1,500.00 Oct, 2014 · 145 pages

Ask Your Question

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: